Assessing Gestational Age in First Trimester Pregnancies Using Ultrasound

Assessing Gestational Age in First Trimester Pregnancies: A Comparison of a New Handheld Wireless Transabdominal Ultrasound to a Portable Transabdominal Ultrasound

The objective of this study is to assess equivalency of the transabdominal Clarius handheld wifi C3 ultrasound (which uses Bluetooth to locate the ipad Mini 5 and then uses wifi direct to show the images) to the current standard of care in Women's Hospital outpatient department the portable Zonare ZS3 in patients presenting in the first trimester of pregnancy.

Study Overview

• Status: Completed
• Conditions: Pregnancy Early

Detailed Description

This is a prospective study in which first trimester participants who are presenting to discuss termination of pregnancy, will consent to have an additional transabdominal ultrasound with the Clarius C3 immediately prior to their standard ultrasound which is performed to date their pregnancy. Participants who are presenting for medical abortion have been prescreened to be estimated to be less than 9 weeks GA. Participants who are being seen prior to surgical abortion will have been screened by nurses based on their last menstrual period or estimated time of conception to estimate their gestational age. Potential participants estimated to be less than 13 weeks GA, will be approached to see if they are interested in participating in the study before they are seen by their health care provider. The name, date of approach, and reason for decline of potential participants who refuse to participate will be documented. If agreeable, the participant will complete consent with a study nurse or medical student for the additional ultrasound.

Participants will then receive the 2 ultrasounds by the same health care provider with the Clarius C3 ultrasound first, then the standard care ultrasound. Occasionally, there may be a different provider doing the Clarius C3 ultrasound when the patient consents.

Participants will receive standard care for medical or surgical abortion. The following information will be documented from their chart:

Height and weight, age, Obstetrical history (Gravida, para, number cesareans, ectopic pregnancies, spontaneous abortions, therapeutic abortions). If they do not have a documented intrauterine pregnancy, the standard questions to rule out possibility of ectopic pregnancy will be determined, and any positive answers will be documented in the chart. Anyone without a documented intrauterine pregnancy (no gestational sac or a gestational sac with no definite crown rump length or yolk sac) will be followed until a final outcome is determined or they are lost to follow up. When the patient has a pregnancy of unknown location (no evidence of a pregnancy inside or outside of the uterus), their data will not be used to compare the two ultrasounds but future outcome will be recorded.

The final outcome of their pregnancy and any complications will be determined within the next 6 weeks with the following potential outcomes:

completed medical abortion, completed surgical abortion (possibily following failed medical abortion), lost to follow up, continuing pregnancy, or ectopic pregnancy.

If a participant is determined to be over 13 weeks GA, they will receive a dating ultrasound with the Clarius C3 ultrasound using biparietal diameter as appropriate but it will not be included in the final study measurements.

• Study Type: Observational
• Enrollment (Actual): 57

Contacts and Locations

Study Locations

• Canada
  • Manitoba
    • Winnipeg, Manitoba, Canada, R3E 0L8
      • Womens Hospital- 735 Notre Dame Ave
    • Winnipeg, Manitoba, Canada, R3H 1R9
      • Women's Hospital 820 Sherbrook St (moved hospitals Dec 2019)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 50 years (Child, Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Patients are presenting for an ultrasound prior to first trimester termination of pregnancy.

Description

Inclusion Criteria:

1. Presenting requesting medical or surgical abortion
2. Estimated to be under 13 weeks gestational age based on last menstrual period or time of conception, or nurses best estimate.
3. Able to provide informed consent with adult supervision of a minor or with an interpreter present

Exclusion Criteria:

1. Unable to provide informed consent

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Can Both Transabdominal Ultrasounds See a Gestational Sac and Yolk Sac or Embryo?	Number of participants with both ultrasounds showing a gestational sac with a yolk sac or embryo	Results will be known immediately after both ultrasounds are completed

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Can Both Transabdominal Ultrasounds Give a Crown Rump Length or Gestational Sac Size to Within 5 Days	Number of participants with both ultrasounds showing a crown rump length or gestational sac measurement within 5 days of error.	Results will be known immediately after both are completed

Collaborators and Investigators

• Sponsor: University of Manitoba

Publications and helpful links

General Publications

• Van den Hof MC, Smithies M, Nevo O, Oullet A. No. 375-Clinical Practice Guideline on the Use of First Trimester Ultrasound. J Obstet Gynaecol Can. 2019 Mar;41(3):388-395. doi: 10.1016/j.jogc.2018.09.020.

Study record dates

Study Major Dates

• Study Start (Actual): June 18, 2019
• Primary Completion (Actual): January 4, 2020
• Study Completion (Actual): April 5, 2020

Study Registration Dates

• First Submitted: May 13, 2019
• First Submitted That Met QC Criteria: May 18, 2019
• First Posted (Actual): May 21, 2019

Study Record Updates

• Last Update Posted (Actual): January 25, 2024
• Last Update Submitted That Met QC Criteria: May 8, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: Ultrasound; pregnancy; first trimester; dating
• Other Study ID Numbers: HS22818 (B2019:034)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No